|
1. Biologie
|
|
|
|
4.14 Dép., diag. & prono. - Thyroïde
|
|
|
Don't Screen For Thyroid Cancer, Task Force Says [NPR]
|
|
|
|
|
|
"If
you look early, you just find a whole new category of patients that has
the disease but is never going to suffer from it at all," says Dr. H.
Gilbert Welch at the Dartmouth Institute for Health Policy and Clinical
Practice. "But they will suffer from the treatment."
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
Roche's Tecentriq fails trial in advanced bladder cancer [Reuters]
|
|
|
|
|
|
The
U.S. Food and Drug Administration had granted accelerated approval for
the drug based on previous trial data on bladder cancer patients whose
disease progressed during or after chemotherapy. The follow-up
IMvigor211 trial was designed to support full approval in the United
States and around the world.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
The Progress of Cancer Immunotherapy: The Tip of the Iceberg [Dana-Farber Cancer Institute]
|
|
|
|
|
|
“Our
task is to figure out the answer to at least two questions. First, why
do only some patients with tumors that can respond to immunotherapy –
like melanoma, lung, bladder and kidney – not respond to immunotherapy?
Why is it only 20 or 30 or 40 percent? Why don’t all of them respond?
And second, why do some cancers not respond at all, like pancreatic,
prostate, ovarian, and breast cancer, glioblastoma, and colon cancer
other than patients with Lynch syndrome?”
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
FDA grants accelerated approval to avelumab for urothelial carcinoma [FDA]
|
|
|
|
|
|
Approval
was based on data from an open-label, single arm, multi-center study
that enrolled 242 patients with locally advanced or metastatic
urothelial carcinoma whose disease progressed on or after platinum-based
therapy or within 12 months of a platinum-containing neoadjuvant or
adjuvant chemotherapy regimen.
|
|
|
|
|
|
|
|
Pfizer immuno-oncology drug wins U.S. approval for bladder cancer [Reuters]
|
|
|
|
|
|
Bavencio,
known chemically as avelumab, was approved for patients with locally
advanced or metastatic bladder cancer whose disease progressed during or
following platinum-containing chemotherapy or within 12 months of
chemotherapy treatment before or after surgery. It is the fourth new
immunotherapy to be approved for advanced bladder cancer.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
Scott Gottlieb wins confirmation as FDA commissioner [STAT]
|
|
|
|
|
|
Will
Gottlieb have to follow Trump’s orders to repeal two regulations for
every new one? Will he have to accept deep budget cuts that could affect
his ability to implement the 21st Century Cures Act? And how far will
Trump push in his stated goal to “slash restraints” at the FDA to speed
up what the president has called a “slow and burdensome” process of drug
approvals?
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
6.8 Communication
|
|
|